According to our findings, cancer patients with low expression of MAP1LC3A, SNCA, and MAPT and high expression of CDK1, AP1S1, CASP3, TMPRSS6, and GSK3B have poor overall survival while patients with high expression of MAP1LC3A, SNCA, and MAPT and low expression of CDK1, AP1S1, CASP3, TMPRSS6, and GSK3B have good overall survival. This evidence concerns the gene MAP1LC3A and cancer.